Complete Genomics, Inc. Announces New Technology Developed to Set Standard for Clinical-Grade Genomes

MOUNTAIN VIEW, Calif., July 11, 2012 (GLOBE NEWSWIRE) -- Complete Genomics, Inc. (Nasdaq:GNOM) today announced that its Long Fragment Read (LFR) technology for whole genome sequencing dramatically improves accuracy, enables fully-phased genomes, and significantly reduces the amount of DNA required for testing. Complete's LFR technology should accelerate the use of whole genome sequencing by physicians to diagnose and treat their patients.